CN112479887B - 马齿苋中一种酯类化合物及其提取分离方法和应用 - Google Patents
马齿苋中一种酯类化合物及其提取分离方法和应用 Download PDFInfo
- Publication number
- CN112479887B CN112479887B CN202011351224.9A CN202011351224A CN112479887B CN 112479887 B CN112479887 B CN 112479887B CN 202011351224 A CN202011351224 A CN 202011351224A CN 112479887 B CN112479887 B CN 112479887B
- Authority
- CN
- China
- Prior art keywords
- purslane
- elution
- methanol
- extraction
- separating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000001855 Portulaca oleracea Nutrition 0.000 title claims abstract description 47
- 241000219304 Portulacaceae Species 0.000 title claims abstract description 46
- -1 Ester compound Chemical class 0.000 title claims abstract description 37
- 238000000926 separation method Methods 0.000 title claims abstract description 26
- 238000000605 extraction Methods 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000004952 Polyamide Substances 0.000 claims abstract description 6
- 229920002647 polyamide Polymers 0.000 claims abstract description 6
- 238000004440 column chromatography Methods 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- 238000010828 elution Methods 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 16
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002024 ethyl acetate extract Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 238000010829 isocratic elution Methods 0.000 claims description 5
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 241001365789 Oenanthe crocata Species 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 102000003914 Cholinesterases Human genes 0.000 abstract description 3
- 108090000322 Cholinesterases Proteins 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 229940048961 cholinesterase Drugs 0.000 abstract description 3
- 239000007791 liquid phase Substances 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 238000010898 silica gel chromatography Methods 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 2
- 238000005191 phase separation Methods 0.000 abstract description 2
- 229910001175 oxide dispersion-strengthened alloy Inorganic materials 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 108010022752 Acetylcholinesterase Proteins 0.000 description 5
- 229940022698 acetylcholinesterase Drugs 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000013375 chromatographic separation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 229960001697 physostigmine Drugs 0.000 description 3
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 244000234609 Portulaca oleracea Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- SZMVXHRECFRCKQ-UHFFFAOYSA-M 2-ethanethioyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=S)OCC[N+](C)(C)C SZMVXHRECFRCKQ-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WYGMGKPKILJUQX-UHFFFAOYSA-N [N+](=O)([O-])C1=C(C(=O)O)C=C(C=C1)SSC=1C=CC(=C(C(=O)O)C1)[N+](=O)[O-].[P] Chemical compound [N+](=O)([O-])C1=C(C(=O)O)C=C(C=C1)SSC=1C=CC(=C(C(=O)O)C1)[N+](=O)[O-].[P] WYGMGKPKILJUQX-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 238000002072 distortionless enhancement with polarization transfer spectrum Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1892—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns the sorbent material moving as a whole, e.g. continuous annular chromatography, true moving beds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及中药提取、分离领域,尤其涉及从马齿苋药材中提取、分离和鉴别出的新化合物及其提取分离方法和应用。本发明提供了一种从马齿苋中提取的(7E,9E)‑6‑氧代十八烷基‑7,9‑二烯酸乙酯及其提取分离方法和应用,该酯类化合物依次采用醇煎煮提取、硅胶柱层析、聚酰胺柱层析、ODS中压柱及Sephadex LH‑20纯化、液相分离制备,该提取分离方法简便,快速,环保,且经该方法分离得到的化合物纯度较高,药理实验证明所得的化合物具有抗肿瘤及抗胆碱酯酶作用,因此所述的一种从马齿苋中提取的新酯类化合物及其盐和衍生物可以作为天然产物开发中药新药,具有广阔的医药应用前景。
Description
技术领域
本发明涉及中药提取、分离领域,尤其涉及从马齿苋药材中提取、分离和鉴别出的新化合物及其提取分离方法,具体为马齿苋中一种酯类化合物及其提取分离方法和应用。
背景技术
马齿苋(Portulaca oleracea L.),又名长命菜、马苋菜,为马齿苋科植物。马齿苋耐旱耐涝,且耐光耐阴,分布广泛,资源丰富,作为药食两用的野生植物备受关注,2015版《中华人民共和国药典》中收载马齿苋的干燥地上部分入药,具有清热解毒、凉血止血、止痢等功效,用于热毒血痢、痈肿疔疮、湿疹、丹毒、蛇虫咬伤、便血、痔血、崩漏下血等。
马齿苋现代药理学研究表明,其具有抗炎止痛、抗菌抗病毒、降血压、降血脂、抗氧化、抗癌、松弛骨骼肌和平滑肌、调节免疫功能等作用。研究表明马齿苋众多化学成分为其多样的药理作用提供了物质基础,马齿苋主要化学成分包括黄酮类、香豆素、萜类、甾类、生物碱、氨基酸、各种色素类和矿物质类等。近年来,许多学者集中于对马齿苋化学成分的含量测定,药效学及药代动力学等研究,然而,在马齿苋中从未见一种新酯类化合物的分离及体内外分析研究报道。
目前从马齿苋中分离出的化学成分大多数是已知的,且结构新颖性较低,因此,对马齿苋中新化合物的开发和分离是亟待需要的。
发明内容
针对上述问题,本发明的目的是提供一种从马齿苋中提取一种新的酯类化合物(7E,9E)-6-氧代十八烷基-7,9-二烯酸乙酯及其提取分离方法和应用,本发明提供的从马齿苋中提取的新化合物经研究发现该酯类化合物具抗肿瘤和抗胆碱酯酶活性,同时该化合物的提取分离方法简便、快速、环保,并且分离得到的化合物纯度高。
为实现上述目的,本发明采用以下技术方案。
一种从马齿苋中提取分离的酯类化合物,所述化合物的分子式为C20H34O3,化学命名为(7E,9E)-6-氧代十八烷基-7 ,9-二烯酸乙酯,化学结构式为:
进一步地,所述从马齿苋中提取分离的酯类化合物的提取分离方法,包括以下步骤。
步骤1、取马齿苋干燥药材,采用醇溶剂提取,醇提液滤过,合并滤液直接加热浓缩,放凉至室温,得药液备用。
步骤2、将步骤1中药液蒸干后上硅胶柱,用乙酸乙酯洗脱,减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物。
步骤3、将步骤2中乙酸乙酯提取物经聚酰胺柱分离,采用乙醇洗脱,乙醇部分蒸干后上硅胶柱,依次用乙酸乙酯-甲醇梯度洗脱得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用。
步骤4、将步骤3中所得物经预处理的ODS柱(Octadecylsilyl,十八烷基硅烷键合硅胶填料)层析分离,用甲醇-水梯度洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,将各显色的洗脱部位分别减压浓缩至干,得到浓缩物备用。
步骤5、将步骤4中所得物再经预处理的葡聚糖凝胶柱(Sephadex LH-20)层析分离,用甲醇洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用。
步骤6、对步骤5中所得浓缩物进行HPLC(高效液相)分离制备,以甲醇和0.1%甲酸的体积比为80:20作为流动相,制备得到一种酯类化合物。
进一步地,所述步骤1中醇溶剂为50%乙醇,提取次数为2次,每次提取回流2小时,乙醇的用量为药材的8~16倍。
进一步地,所述步骤2中所用流动相洗脱程序为等度洗脱。
进一步地,所述步骤3中用水和乙醇的体积比为5:95等度洗脱。
进一步地,所述步骤3中乙酸乙酯和甲醇的体积比为5:1和2:1梯度洗脱。
进一步地,所述步骤4中甲醇和水的体积比为60:40、70:30、80:20、90:10和100:0梯度洗脱。
进一步地,所述ODS柱与葡聚糖凝胶的预处理过程为甲醇浸泡过24小时,上柱,用甲醇洗至滴入水中无混浊,再以初始流动相平衡。
进一步地,所述步骤5中甲醇洗脱程序为等度洗脱。
进一步地,所述从马齿苋中提取具分离的酯类化合物及其盐和衍生物在制备抗肿瘤和抗胆碱酯酶药物中的用途。
所述抗肿瘤和抗胆碱酯酶产品包括但不限于药物。
与现有技术相比本发明的有益效果如下。
本发明中所述马齿苋新化合物的分离和药理活性研究未被现有论文期刊所报道,本发明提供来源于马齿苋的新化合物及一种针对本发明新化合物的提取分离方法,采用醇提取、聚酰胺柱、硅胶柱层析、ODS中压柱及HPLC进行分离纯化与制备,成功提取分离出新的化合物,该方法操作步骤仅为六步,操作方法简便及快速,提取分离过程主要采用醇提取及乙酸乙酯洗脱,工艺方法环保,且经该方法分离得到的化合物纯度较高均大于90%,此外经研究表明以上化合物具有显著的抗肿瘤和抗胆碱酯酶活性,因此本发明新化合物及其衍生物可以作为其他化合物合成先导物,以及新药开发和药理活性研究的原料,亦可用于制备抗肿瘤和抗胆碱酯酶等药物。
附图说明
图1为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物1H-NMR光谱图。
图2为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物13C-NMR光谱图。
图3为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的核磁共振碳谱(DEPT)光谱图。
图4为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的核磁共振1H-1HCOSY光谱图。
图5为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的核磁共振HMBC光谱图。
图6为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的核磁共振HSQC光谱图。
图7为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的核磁共振NOESY光谱图。
图8为本发明马齿苋中具有抗肿瘤和抗胆碱酯酶活性的酯类新化合物的高分辨质谱图。
具体实施方式
实施例1从马齿苋中提取分离的酯类化合物及其提取分离方法。
一种从马齿苋中提取分离的酯类化合物,分子式为C20H34O3,命名为(7E,9E)-6-氧代十八烷基-7,9-二烯酸乙酯,化学结构式为:
表1为该新化合物的核磁数据:1H-NMR与13C-NMR在DMSO中。
表1 .本发明新化合物的核磁数据
化合物为淡黄色油状物,易溶于甲醇,不溶于水。HRESI(+)TOFMS给出m/z:323.2584[M+H]+的准分子离子峰,分子量为323.2586。结合1H-NMR,13C-NMR以及DEPT数据,推测该化合物可能的分子式为C20H34O3,不饱和度为4。13C-NMR谱和DEPT谱显示20个碳信号,分别为2个CH3(δ:13.82;14.10)、12个CH2(δ:21.92;23.53;24.40;24.56;28.08;28.08;28.42;30.84;32.38;33.45;39.24;59.58)、4个CH(δ128.05;128.96;142.74;145.31)、2个季碳(δ:172.53;200.10)。
在以氘代DMSO为溶剂的1H-NMR谱显示两个甲基信号,为δ0.85(3H,t,J=6.90),δ1.17(3H,t,J=7.20);12个亚甲基信号,分别为δ1.25(8H,m),δ1.48(8H,m),δ2.17(2H,m),δ2.25(2H,t,J=7.02),δ2.54(2H,t,J=7 .50),δ4.04(2H,t,J=7.20);4个次甲基信号分别为δ6.10(1H,d,J=15.54);δ6.26(2H,m);δ7.18(1H,m);根据13C和HSQC谱表明存在2个甲基、12个脂肪族亚甲基和4个次甲基;13C和HMBC谱图显示,H-2和C-1,C-3,C-4;H-3和C-1,C-2,C-5;H-4和C-2,C-5,C-6;H-5和C-3,C-4,C-6;H-7和C-6,C-9;H-8和C-6,C-10;H-9和C-7,C-8,C-11;H-10和C-8,C-11;H-11和C-9,C-10,C-12,C-14;H-12和C-11,C-14,C-15;H-13和C-14,C-15,C-16;H-14和C-15,C-16;H-15和C-14,C-16,C-17;H-16和C-14,C-15,C-17,C-18;H-17和C-15,C-16,C-18;H-18和C-16,C-17相关。4个次甲基信号δ6.10(1H,d,J=15.54);δ6.26(2H,m),说明了双键的存在,更证明了与羰基碳相连使得化学位移偏高,根据以上信息,可确定此新化合物为上述结构,并命名为(7E,9E)-6-氧代十八烷基-7,9-二烯酸乙酯。
本发明还提供所述从马齿苋中提取具分离的酯类化合物的提取分离方法,具体步骤为。
步骤1、称取马齿苋干燥药材250kg,采用50%乙醇回流提取,50%乙醇用量为药材的8~16倍,回流提取两次,每次2h,减压回收乙醇,放凉至室温,得药液备用。
步骤2、将步骤1中所得药液蒸干后经硅胶柱层析分离,用乙酸乙酯(115L)等度洗脱,其中硅胶为100-200目,40℃以下减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物。
步骤3、将步骤2中乙酸乙酯提取物经聚酰胺柱分离,采用乙醇梯度洗脱,乙醇蒸干后经硅胶柱层析分离,其中硅胶为200~300目,依次用乙酸乙酯-甲醇(5:1、2:1,v:v)梯度洗脱,共得到20个部位(即共得到15个瓶,每瓶500mL),经薄层色谱进行检测,显色,合并显色的1~9洗脱部位,将合并后的1~9部位经40℃以下减压浓缩至干,备用。
步骤4、将步骤3中所得物再经预处理的ODS中压柱层析分离(Octadecylsilyl,十八烷基硅烷键合硅胶填料),其中填料粒度为20~40μm,用甲醇-水(60/40,70/30,80/20,90/10,100/0,v/v)梯度洗脱(加压,使流速为1mL/min,温度为室温),得到25个部位(即梯度洗脱得25个瓶,每瓶100mL),经薄层色谱进行检测,显色,将显色的20~25部位保留,50℃以下减压浓缩至干,备用。
步骤5、将步骤4中所得物再经预处理的葡聚糖凝胶柱层析分离(Sephadex LH-20),用甲醇洗脱,得到20洗脱部位(即共得到20个瓶,每瓶50mL),经薄层色谱进行检测,显色,将显色的8~11部位保留,50℃以下减压浓缩至干,备用,得到新化合物。所述ODS与葡聚糖凝胶的预处理过程为甲醇浸泡过24h,上柱,用甲醇洗至滴入水中无混浊,再以初始流动相平衡。
步骤6、将步骤5中所得新化合物经HPLC分离制备,以甲醇:0.1%甲酸(80:20,v/v)作为流动相,检测波长为210nm,280nm,分离制备得到本发明新化合物,归一法测定纯度均为90~99%。
实施例2本发明新酯类化合物的抗肿瘤作用。
1主要材料。
1.1药品和试剂。
实验所用新酯类化合物由上述方法制备,纯度为90~99%,精密称取,用DMSO稀释至下述各剂量组所需溶液。DMEM高糖培养基、胎牛血清(美国Hyclone公司);青霉素、链霉素(杭州四季青公司)。
1.2细胞株。
人结肠癌细胞Caco-2、人乳腺癌细胞MCF-7、人胃癌细胞BGC-823、人肺腺癌细胞SPC-A1、人肝癌细胞BEL-7402、人***细胞Hela-229、卵巢癌细胞Ho-8910、人类口腔表皮样癌细胞KB(中科院上海细胞库)。
1.3分组。
分为对照组、实验组和调零组(含DMSO溶媒的培养液)。
2实验方法。
2.1细胞培养。
DMEM高糖培养基,加入l0%的胎牛血清,l%抗菌素(100U/mL青霉素和100μg/mL链霉素),置于37℃、5%CO2培养箱中培养。
2.2MTT法检测细胞增殖。
取对数生长期细胞接种于96孔培养板中,细胞密度为1×104个/mL,每孔100μL,温度37℃,5%CO2条件下培养过夜后,实验组加入不同浓度的本发明新化合物,每组设3个复孔,加药后置于37℃,5%CO2培养箱中培养48h。将含药培养液吸去,加入体积比为4:1的无血清培养液和MTT(终质量浓度为5mg/mL)共100mL,继续孵育4h,小心吸去上清液后,每孔加入DMSO 150μL,放于震荡器上震荡以使结晶完全溶解(5min),酶标仪在570nm波长下检测各孔的吸光度(A)值。然后,计算各浓度化合物对细胞生长的抑制率,抑制率公式:细胞生长抑制率=(1-A加药孔/A对照孔)×100%,再应用SPSS软件处理数据,将抑制率对药物浓度作曲线,计算IC50值。
3实验结果。
实验结果表明本发明两种新生物碱化合物对人结肠癌细胞Caco-2、人乳腺癌细胞MCF-7、人胃癌细胞BGC-823、人肺腺癌细胞SPC-A1、人肝癌细胞BEL-7402、人***细胞Hela-229、卵巢癌细胞Ho-8910、人类口腔表皮样癌细胞KB、的增殖具有抑制作用,且随药物浓度增大,抑制率也明显升高,即呈浓度依赖。本发明两种新生物碱化合物对上述八种肿瘤细胞IC50值见表2。
表2.本发明新化合物对肿瘤细胞的抑制作用
实施例3本发明新化合物的抗胆碱酯酶作用。
1、主要材料。
1.1药品和试剂。
实验所用新化合物由上述方法制备,纯度为90~99%,磷酸二氢钠、磷酸氢二钠(国药集团化学试剂有限公司),毒扁豆碱(瀚香生物科技),磷5,5’-二硫代双(2-硝基苯甲酸) (Dithiobisnitrobenzoic acid,DTNB,上海金穗生物科技有限公司),乙酰胆碱酯酶(AChE)和碘化硫代乙酰胆碱(Acetylthiocholine iodide,ATCI,大连美仑生物技术有限公司)。
1.2分组。
分为阴性对照组、阳性对照组和实验组,各一组。
2实验方法。
2.1样品准备。
分别精密称取样品和毒扁豆碱0.11mg,分别以甲醇为溶剂,配置成2.5、5.0、10.0、20.0、40uM五个梯度浓度。分别精密称取7.8005g的磷酸二氢钠和17.907g的磷酸氢二钠,用蒸馏水定容至500mL,取26.5mL的磷酸二氢钠和473.5mL的磷酸氢二钠,配制成500mL PBS(0.1M pH=8.0);精密称取0.0594g DTNB,加入10mL的PBS,配制成DTNB溶液(15mmol/L);精密称取0.01g AChE,加入10mL PBS,配制成AChE溶液(0.2u/mL);精密称取0.044mg ATCI,用蒸馏水定容至10mL,配制成ATCI溶液(15mmol/L)。
2.2改进的Ellman方法测定抗胆碱酯酶活性。
在96孔酶标板中依次加入140μL PBS(0.1M pH=8.0),10μL DTNB(15mmol/L),15μL AChE(0.2u/mL),20μL样品溶液。阴性对照组实验用甲醇代替样品,阳性对照组实验用毒扁豆碱代替样品。37℃孵育10min后,加10uL ATCI(15mmol/L)。20℃孵育10min后,用酶标仪在410nm下测定其吸光度值。根据下式计算抑制率:抑制率(%)=(空白组-样品)/空白组×100%。
3实验结果。
实验结果如表3所示。实验结果表明本发明化合物有抗胆碱酯酶作用。
表3 .本发明抗胆碱酯酶抑制活性
综上所述,本发明提供了一种从马齿苋中提取的新酯类化合物及其提取分离方法,该酯类化合物依次采用醇煎煮提取、硅胶柱层析、聚酰胺柱层析、ODS中压柱及SephadexLH-20纯化、液相分离制备,该方法简便,快速,环保,且经该方法分离得到的化合物纯度较高,由于所得化合物从常用中药马齿苋中提取出来,其具有抗肿瘤及抗胆碱酯酶作用,因此本发明提供的一种从一种新酯类化合物及其盐和衍生物可以作为天然产物开发中药新药,具有广阔的前景。
Claims (9)
2.如权利要求1所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,具体包括以下步骤:
步骤1、取马齿苋干燥药材,采用醇溶剂提取,醇提液滤过,合并滤液直接加热浓缩,放凉至室温,得药液备用;
步骤2、将步骤1中药液蒸干后上硅胶柱,用乙酸乙酯洗脱,减压回收乙酸乙酯至浸膏,得到乙酸乙酯提取物;
步骤3、将步骤2中乙酸乙酯提取物经聚酰胺柱分离,采用体积比为5:95的水和乙醇混合物等度洗脱,乙醇部分蒸干后上硅胶柱,依次用乙酸乙酯-甲醇梯度洗脱得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用;
步骤4、将步骤3中所得物经预处理的ODS柱层析分离,用甲醇-水梯度洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,将各显色的洗脱部位分别减压浓缩至干,得到浓缩物备用;
步骤5、将步骤4中所得物再经预处理的葡聚糖凝胶柱层析分离,用甲醇洗脱,得到若干洗脱部位,经薄层色谱进行检测,显色,合并显色的洗脱部位,将合并后的洗脱部位经减压浓缩至干,备用;
步骤6、对步骤5中所得浓缩物进行HPLC分离制备,以甲醇和0.1%甲酸的体积比为80:20的混合物作为流动相,制备得到所述的酯类化合物。
3.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述步骤1中醇溶剂为50%乙醇,提取次数为2次,每次提取回流2小时,乙醇的用量为药材的8~16倍。
4.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述步骤2中所用乙酸乙酯洗脱为等度洗脱。
5.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述步骤3中梯度洗脱的乙酸乙酯和甲醇的体积比为5:1和2:1。
6.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述步骤4中梯度洗脱的甲醇和水的体积比为60:40、70:30、80:20、90:10和100:0。
7.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述ODS柱与葡聚糖凝胶的预处理过程为甲醇浸泡过24小时,上柱,用甲醇洗至滴入水中无混浊,再以初始流动相平衡。
8.如权利要求2所述的从马齿苋中提取分离的酯类化合物的提取分离方法,其特征在于,所述步骤5中甲醇洗脱为等度洗脱。
9.如权利要求1所述的从马齿苋中提取具分离的酯类化合物在制备抗肿瘤和抗胆碱酯酶药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011351224.9A CN112479887B (zh) | 2020-11-26 | 2020-11-26 | 马齿苋中一种酯类化合物及其提取分离方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011351224.9A CN112479887B (zh) | 2020-11-26 | 2020-11-26 | 马齿苋中一种酯类化合物及其提取分离方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112479887A CN112479887A (zh) | 2021-03-12 |
CN112479887B true CN112479887B (zh) | 2022-05-17 |
Family
ID=74935328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011351224.9A Active CN112479887B (zh) | 2020-11-26 | 2020-11-26 | 马齿苋中一种酯类化合物及其提取分离方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112479887B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114369022B (zh) * | 2021-06-09 | 2022-11-11 | 辽宁中医药大学 | 马齿苋中一种有机酸类化合物及其提取分离方法 |
CN113968785B (zh) * | 2021-11-23 | 2022-09-30 | 辽宁中医药大学 | 马齿苋中一种含氧苯甲酸及其提取分离方法与应用 |
CN115073295B (zh) * | 2022-07-21 | 2023-12-26 | 山东大学 | 马齿苋中不饱和脂肪酸及其提取分离方法和应用 |
CN115716790B (zh) * | 2022-12-13 | 2023-06-02 | 辽宁中医药大学 | 马齿苋中一种酰胺酯类生物碱的提取分离方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643403A (zh) * | 2009-04-10 | 2010-02-10 | 陈海燕 | 一种从马齿苋中提取亚麻酸的方法 |
CN102173987A (zh) * | 2011-03-07 | 2011-09-07 | 东北师范大学 | 楸皮新酸及其衍生物和它们的制备方法及医学用途 |
CN102516066A (zh) * | 2011-12-22 | 2012-06-27 | 东北师范大学 | Ostopanic acid类似物及制备方法及用途 |
CN110194755A (zh) * | 2019-04-03 | 2019-09-03 | 辽宁中医药大学 | 马齿苋中化合物Oleracone H及其提取分离方法及其与应用 |
CN110294733A (zh) * | 2019-04-03 | 2019-10-01 | 辽宁中医药大学 | 马齿苋中一种含过氧键化合物Oleracone I及其提取分离方法与应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101173289B1 (ko) * | 2010-05-04 | 2012-08-10 | (주)산엔들 | 초임계 이산화탄소 추출을 이용하여 식물로부터 오메가 지방산 함유 추출물의 제조방법 |
-
2020
- 2020-11-26 CN CN202011351224.9A patent/CN112479887B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101643403A (zh) * | 2009-04-10 | 2010-02-10 | 陈海燕 | 一种从马齿苋中提取亚麻酸的方法 |
CN102173987A (zh) * | 2011-03-07 | 2011-09-07 | 东北师范大学 | 楸皮新酸及其衍生物和它们的制备方法及医学用途 |
CN102516066A (zh) * | 2011-12-22 | 2012-06-27 | 东北师范大学 | Ostopanic acid类似物及制备方法及用途 |
CN110194755A (zh) * | 2019-04-03 | 2019-09-03 | 辽宁中医药大学 | 马齿苋中化合物Oleracone H及其提取分离方法及其与应用 |
CN110294733A (zh) * | 2019-04-03 | 2019-10-01 | 辽宁中医药大学 | 马齿苋中一种含过氧键化合物Oleracone I及其提取分离方法与应用 |
Non-Patent Citations (1)
Title |
---|
JA, a new type of polyunsaturated fatty acid isolated from Juglans;Xiu-Li Gao, et al.;《Apoptosis》;20151130;第21卷;第340-350页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112479887A (zh) | 2021-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112479887B (zh) | 马齿苋中一种酯类化合物及其提取分离方法和应用 | |
CN112300000B (zh) | 马齿苋中一种具有抗肿瘤和抗胆碱酯酶活性的酯类化合物及其提取分离方法和应用 | |
CN109897077B (zh) | 马齿苋中化合物Oleraciamide E及其提取分离方法与应用 | |
CN112409307B (zh) | 马齿苋中化合物Olerafuran A及其提取分离方法和用途 | |
CN110272342B (zh) | 马齿苋中一种萘酸化合物及其提取分离方法与用途 | |
CN110272369B (zh) | 马齿苋中一种吡咯二羧酸类化合物及其提取分离方法与用途 | |
CN109824568B (zh) | 马齿苋中两种吲哚类新生物碱化合物及其提取分离方法与应用 | |
CN108084060B (zh) | 马齿苋中生物碱oleraurea及其提取分离方法 | |
CN110407847B (zh) | 一种从土曲霉中获得的azaphilones类化合物及其制备和应用 | |
CN115716790B (zh) | 马齿苋中一种酰胺酯类生物碱的提取分离方法及其应用 | |
CN111303154B (zh) | 马齿苋中一种具有抗炎活性生物碱及其提取分离方法与用途 | |
CN111217773B (zh) | 马齿苋中一种呋喃环类化合物及其提取分离方法与用途 | |
CN112300104B (zh) | 马齿苋中一种木脂素类化合物及其提取分离方法和应用 | |
CN113321618B (zh) | 马齿苋中三种生物碱类化合物及其提取分离方法 | |
CN113264886B (zh) | 马齿苋中一种哒嗪类化合物的提取分离方法及其应用 | |
CN109942481B (zh) | 马齿苋中化合物Oleraisoindole A及其提取分离方法与应用 | |
CN115724812B (zh) | 马齿苋中一种呋喃酯类生物碱的提取分离方法及其应用 | |
CN114989084B (zh) | 马齿苋中一种四氢异喹啉类生物碱的提取分离方法及其应用 | |
CN114369022B (zh) | 马齿苋中一种有机酸类化合物及其提取分离方法 | |
CN110194755B (zh) | 马齿苋中化合物Oleracone H及其提取分离方法及其与应用 | |
CN109824685B (zh) | 马齿苋中化合物oleracone G及其提取分离方法与应用 | |
CN110294733B (zh) | 马齿苋中一种含过氧键化合物Oleracone I及其提取分离方法与应用 | |
CN113968862A (zh) | 马齿苋中两种新生物碱及其提取分离方法 | |
CN113416122B (zh) | 马齿苋中一种芳基类化合物的提取分离方法及其应用 | |
CN113968817B (zh) | 马齿苋中两种四氢异喹啉的提取分离方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |